Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2011

View Archived Issues

Sanofi discloses novel agents for diabetic foot ulcers

Novel Novartis product enters phase I/II trial in healthy subjects and patients with diabetes

Roche discovers new phosphodiesterase 10A inhibitors

New histone deacetylase 9 inhibitors claimed

Novel B-raf inhibitors patented by Selexagen

NCCU patents new beta-nerve growth factor enhancers

FDA clears Newron to conduct first-in-human study of add-on therapy for schizophrenia

U.S. Department of Defense funds development of NeoStem stem cell technology for osteoporosis

New urine-based biomarker test predicts risk of prostate cancer in men with elevated PSA

GSK submits sNDA in U.S. for use of Horizant

Pluristem's agreement with United Therapeutics for PLX cells is effective

Amarin reaches SPA agreement with FDA for phase III REDUCE-IT trial

Array BioPharma and Genentech enter agreement for Chk1 program

NCI to sponsor clinical trials of Pharmacyclics BTK inhibitor

Ironwood Pharmaceuticals and Forest Laboratories submit linaclotide NDA for two indications

Novel injectable coacervate induces angiogenesis in vivo

Enobia raises funds for development of ENB-0040

Chugai files application for additional indication for Kytril in Japan

ThromboGenics expects ocriplasmin filings in U.S. and E.U. before year-end

Adventrx receives FDA complete response letter for Exelbine

New phase I trial of anticancer drug TKM-PLK1 cleared by FDA

Glenmark Pharmaceuticals initiates global phase IIb trials of revamilast

GWAS identifies new lung cancer susceptibility loci in Chinese population

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.